Jingfeng Pharmaceutical(000908)2022-12-03 09:06Group 1: Investor Relations Activities - The investor relations activity involved specific research with multiple investment firms including Zezhi Investment Management Co., Ltd. and Huajia Fund Management Co., Ltd. [1] - The meeting took place on October 10, 2018, from 8:30 to 11:00 at China Resources Tower, Shanghai [1]. Group 2: Company Leadership - Key personnel present included Chairman and CEO Ye Xiangwu, Vice President and Chief Accountant Cong Shufen, and Vice President and Chief Engineer Ma Xianpeng [2]. - The meeting also included founders of SunGen Pharma LLC, Dr. Liu Hongbin and Dr. Huang He, who provided insights into their company [2]. Group 3: Collaboration with SunGen Pharma - SunGen Pharma chose to collaborate with Jingfeng Pharmaceutical due to shared corporate philosophy and future development plans that align with mutual interests [2][3]. - Jingfeng's complete industrial chain in production, research, and sales supports SunGen's operational development [3]. Group 4: Company Positioning and Strategy - SunGen is positioned as a light-asset pharmaceutical company with core technology and market control, focusing on both technology and sales [3]. - The company adheres to high standards in selecting strategic partners, ensuring compliance with FDA standards [4]. Group 5: Product Selection and Risk Management - Product selection is critical for the company, relying on market conditions and management experience to choose safe and controllable products [4]. - The company has established a comprehensive risk control mechanism, including a tiered supplier system for raw materials to ensure quality and stability [5]. Group 6: Shareholding and Employee Engagement - Founders hold 49% of the company's shares, linking company interests with employee benefits to enhance operational efficiency [5]. - This structure aims to create a stable core talent team and share the company's development outcomes [5].